Aphasia, Primary Progressive
A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)
Subtype terms (1)
More specific conditions that are subtypes of Aphasia, Primary Progressive in the MeSH hierarchy.
- Primary Progressive Nonfluent Aphasia
5 drugs (1 approved, 4 experimental)
Drugs by status
Phase 2 trials (2)
Phase 1 trials (3)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (26)
- Avid Radiopharmaceuticals
- Cyclotherapeutics
- FORUM Pharmaceuticals Inc
- National Institutes of Health (NIH)
- National Human Genome Research Institute (NHGRI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Chang Gung University
- Cornell University
- HealthPartners Institute
- University of Florida
- Columbia University
- University of Minnesota
- Salford Royal Foundation NHS Trust
- University of Oxford
- CHU Purpan
- University of Nantes
- University of Paris
- Washington University in St. Louis
- University of Western Ontario
- Canadian Institutes of Health Research (CIHR)
- Berry Consultants
- Johnson and Johnson
- University of Rennes
- The Weston A. Price Foundation
- IntraBio Inc
- Prevail Therapeutics
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (3)